← Human Trials & Peer-Reviewed Studies
Tumor shrinkage with lanreotide Autogel [amount hidden] as primary therapy in acromegaly: results of a prospective multicenter clinical trial
Plain-language guide to PMID 24423301 (2014): open-label and multicenter clinical trial, phase iii study of Somatostatin and Lanreotide.
Key Facts
- PMID
- 24423301
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2014
- Study type
- Clinical Trial, Phase III
- Authors
- Caron PJ et al. (8 authors)
- DOI
- 10.1210/jc.2013-3318
- Registered trial
- NCT00690898
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin and Lanreotide in this clinical trial, phase iii publication.
The aim of the study was to better characterize the effects of primary lanreotide Autogel treatment on tumor size in patients with GH-secreting macroadenomas.
Why It Was Studied
Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly.
There are also limited data for the long-acting lanreotide formulation.
Who Took Part
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
Treatment-naïve acromegalic patients with GH-secreting macroadenomas participated in the study.
How the Study Was Run
The researchers set it up as a open-label and multicenter study.
Being open-label, the Somatostatin study did not mask who received what.
Running at several centres spread the Somatostatin study over different clinics and patient groups.
PRIMARYS was a 48-week, multicenter, open-label, single-arm study.
The study was conducted at specialist endocrine centers.
What Was Measured
Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly.
PubMed files the paper under topics including Acromegaly, Adenoma, Gels, Growth Hormone-Secreting Pituitary Adenoma, Neoadjuvant Therapy, Peptides, Cyclic and Somatostatin.
What This Means in Plain Language
The paper is an open-label and multicenter study of Somatostatin and Lanreotide.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Somatostatin compound page and the Lanreotide compound page.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.